Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$257K Sell
731
-175
-19% -$62.4K 0.02% 257
2025
Q4
$297K Buy
906
+45
+5% +$14.3K 0.02% 237
2025
Q3
$243K Buy
+861
New +$250K 0.02% 277
2024
Q2
Sell
-764
Closed -$217K 247
2024
Q1
$217K Sell
764
-480
-39% -$140K 0.02% 253
2023
Q4
$358K Buy
+1,244
New +$339K 0.03% 180
2023
Q3
Sell
-1,341
Closed -$298K 290
2023
Q2
$298K Sell
1,341
-70
-5% -$16.2K 0.02% 310
2023
Q1
$341K Buy
1,411
+37
+3% +$9.08K 0.02% 280
2022
Q4
$361K Buy
1,374
+407
+42% +$109K 0.03% 275
2022
Q3
$218K Sell
967
-30
-3% -$7.27K 0.02% 365
2022
Q2
$243K Buy
997
+80
+9% +$19.6K 0.02% 358
2022
Q1
$222K Buy
+917
New +$211K 0.01% 442

Other funds holding AMGN

American Trust's AMGN Position: Q1 2026 in Review

American Trust reduced its Amgen (AMGN) stake by 19% in Q1 2026, selling an estimated $62.4K and leaving 731 shares worth $257K. The position accounts for 0.02% of the portfolio, ranked #257.

American Trust first reported a position in AMGN in Q1 2022 and has held it in 11 quarters since. The position peaked at $361K in Q4 2022. 3,131 funds tracked by Wall St. Rank hold AMGN as of Q1 2026.

  • American Trust held 731 shares of Amgen worth $257K as of Q1 2026.
  • American Trust sold 175 Amgen shares in Q1 2026, an estimated $62.4K.
  • Amgen made up 0.02% of American Trust's portfolio in Q1 2026, its #257 holding.
  • American Trust first reported a position in Amgen in Q1 2022 and has held it in 11 quarters since.
  • American Trust's Amgen position peaked at $361K in Q4 2022.
  • 3,131 funds tracked by Wall St. Rank held Amgen as of Q1 2026.

Based on American Trust's 13F filing for Q1 2026, filed 1 May 2026.